No material company-specific news briefings were available for Amgen Inc. in the 30-day period leading to 27 September 2026. The report was triggered by material institutional position changes identified in recent 13F filings, as detailed in the holdings section below [Brief - 2026-09-19].
Amgen's trailing twelve-month revenue stood at $38.10 billion as of 30 June 2026, representing year-over-year growth of 9.53%. Net income for the same period was $8.74 billion, with a net margin of 22.95% and an operating margin of 29.99%. Gross margin was recorded at 47.46%. Earnings per share grew 64.91% year-over-year. The company held $13.99 billion in cash against total debt of $59.30 billion. Market capitalisation was approximately $224.14 billion, with a price-to-earnings ratio of 25.77 [SEC 10-Q - AMGN - 2026-06-30].
Several notable institutional position changes were recorded in recent 13F filings. Citadel added approximately 60% to its existing AMGN position, while AQR Capital increased its holdings by approximately 97%. Bridgewater added approximately 48% to its position. Conversely, Millennium reduced its AMGN position by approximately 36% over the same reporting period [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Bridgewater - Q2 2026] [SEC 13F - Millennium - Q2 2026]. No insider transaction data was available for inclusion in this report.
The prevailing macro environment as of the report date shows the 10-year US Treasury yield (DGS10) at 5.18% and the 2-year yield (DGS2) at 4.87%, producing a normal yield curve spread of 31 basis points [FRED DGS10] [FRED DGS2]. Amgen carries a substantial debt load of $59.30 billion, making the interest rate environment a relevant contextual factor for its financing costs [SEC 10-Q - AMGN - 2026-06-30].